Neoadjuvant Nivolumab Plus Relatlimab for Resectable Cutaneous Squamous Cell Carcinoma
The Neo-SCC Trial
The Neo-SCC Trial
Georgina Long, MBBS, PhD, Melanoma Institute Australia, Sydney, describes a trial currently in progress to evaluate the combination of nivolumab plus relatlimab in the neoadjuvant setting for patients with resectable cutaneous squamous cell carcinoma.
Transcript:
Hi, my name's Professor Georgina Long from Melanoma Institute Australia and the University of Sydney at the ASCO 2025. We will be presenting a trial in progress poster on a trial that is an investigator led trial from Australia Melanoma Institute, and this is called the Neo-SCC trial.
In this trial, patients with cutaneous squamous cell carcinoma [SCC] receive combination nivolumab and relatlimab as a neoadjuvant therapy. We know that anti–PD-1, single-agent, has activity both in advanced cutaneous SCC but also in the neoadjuvant setting, but we'd like to improve upon that. Hence, the combination of nivolumab and relatlimab will be explored in this setting. Translational endpoints are key, so biomarkers both peripherally in the blood but also in the tissue before and after neoadjuvant therapy.
Source:
Gonzalez M, Van Akkooi A, Bennett T, et al. A phase 2 study to determine the clinical and pathological (path) response to neoadjuvant nivolumab (nivo) and relatlimab (rela) in stage II to IV (M0) resectable cutaneous squamous cell carcinoma (Neo-SCC). Presented at the 2025 ASCO Annual Meeting. May 30-June 3, 2025; Chicago, IL. Abstract: TPS9610
